---
schema_version: "secwatch.filing_event.v1"
accession: "0001438533-21-000047"
form_type: "8-K"
ticker: "TVTX"
cik: "0001438533"
company_name: "Travere Therapeutics, Inc."
filed_at: "2021-10-12T23:59:59+00:00"
generated_at: "2026-06-28T21:24:51.465458+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# CMO Noah Rosenberg to step down Dec 31, 2021; to serve as executive advisor through 2022

## Summary
- Noah Rosenberg will transition from CMO to executive advisor effective Dec 31, 2021.
- He will continue as CMO until year-end, then advise through 2022 on clinical trial oversight and regulatory submissions.
- Transition agreement provides severance benefits consistent with existing employment agreement.
- Post-transition consulting includes monthly retainer through May 2022, hourly fees June-Dec 2022, and success bonus tied to FDA acceptance of sparsentan NDA.
- Stock awards continue vesting; severance amendments extend certain benefits to 18 months.

## SEC filing metadata
- accession: 0001438533-21-000047
- form_type: 8-K
- ticker: TVTX
- cik: 0001438533
- company_name: Travere Therapeutics, Inc.
- filed_at: 2021-10-12T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1438533/000143853321000047/0001438533-21-000047-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1438533/000143853321000047/tvtx-20211012.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001438533-21-000047
- JSON: https://secwatch.observer/filing/0001438533-21-000047.json
- Plain text: https://secwatch.observer/filing/0001438533-21-000047.txt

## Key facts
- Executive change
  Noah Rosenberg changed role as executive advisor at Travere Therapeutics, Inc..
  - Action: transitioning
  - Role: executive advisor
  source text: On October 12, 2021, Travere Therapeutics, Inc. (the “Company”) announced that its chief medical officer, Noah Rosenberg, M.D., will be transitioning to an executive advisor role at the end of 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1438533/000143853321000047/0001438533-21-000047-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.